glp 1 obesity GLP‑1 real‑world data for obesity: A new standard for metabolic care Weighing the risk of GLP-1

Most GLP-1 agonists (semaglutide, liraglutide, dulaglutide, tirzepatide) do not require dose adjustment for mild-to-moderate renal impairment, though caution is warranted in severe renal impairment

doi: 10.1155/2022/1428817 [DOI] [PMC free article] [PubMed] [Google Scholar] 85.Li Q, Jia M, Yan Z, et al

The purpose is educational, and there is typically no formal testimony or cross-examination

However, doctors can still choose to prescribe these medications off-label for weight loss use

The result of steatosis and inflammation is fibrosis, as we have mentioned in Section 3.1

The markedly reduced risk here for alcohol use disorder patients taking GLP-1 agonists suggests that this class of drugs might actually be more effective than the current crop of officially approved medications for treating alcohol addiction